Mark Kaufmann is Ardelyx’s Chief Financial Officer. He has served that role since May 2014 and formerly served as its Chief Business Officer from August 2011 until May 2014. Mr. Kaufmann has over twenty years of experience in the biopharmaceutical industry in both the U.S. and Canada in business, corporate development and financial roles. From 2008 to 2010, Mr. Kaufmann was President and Chief Executive Officer of Allostera Pharma Inc., a preclinical company focused on autoimmune diseases. Prior to joining Allostera, Mr. Kaufmann was President and Chief Executive Officer of Celmed BioSciences, Inc., a biopharmaceutical company. Prior to Allostera, Mr. Kaufmann was VP Corporate Development at Nexia Biotechnologies and, prior to that, Chief Financial Officer of Conceptis Technologies. Mr. Kaufmann started his career as Director of Strategic Planning and Investor Relations at MedImmune in 1994. Mr. Kaufmann received a B.A. in Biochemical Sciences from Harvard University and a M.B.A. from the University of Michigan School of Business.